ALTME Stock Overview
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
TME Pharma N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.31 |
52 Week High | €2.20 |
52 Week Low | €0.19 |
Beta | 1.53 |
1 Month Change | -6.27% |
3 Month Change | 31.38% |
1 Year Change | -68.28% |
3 Year Change | -99.27% |
5 Year Change | -99.60% |
Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
ALTME | FR Biotechs | FR Market | |
---|---|---|---|
7D | 8.8% | 1.0% | 0.4% |
1Y | -68.3% | -1.8% | 9.6% |
Return vs Industry: ALTME underperformed the French Biotechs industry which returned -1.8% over the past year.
Return vs Market: ALTME underperformed the French Market which returned 10.6% over the past year.
Price Volatility
ALTME volatility | |
---|---|
ALTME Average Weekly Movement | 17.5% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.2% |
10% most volatile stocks in FR Market | 9.8% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALTME's share price has been volatile over the past 3 months.
Volatility Over Time: ALTME's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 13 | Aram Mangasarian | https://www.tmepharma.com |
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
TME Pharma N.V. Fundamentals Summary
ALTME fundamental statistics | |
---|---|
Market cap | €8.74m |
Earnings (TTM) | -€8.46m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs ALTME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALTME income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €8.46m |
Earnings | -€8.46m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.30 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -1,354.0% |
How did ALTME perform over the long term?
See historical performance and comparison